Article
TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients.
BMC cancer - 8 Mar 2012
Körner Christian, Riesner Katarina, Krämer Benjamin, Eisenhardt Marianne, Glässner Andreas, Wolter Franziska, Berg Thomas, Müller Tobias, Sauerbruch Tilman, Nattermann Jacob, Spengler Ulrich, Nischalke Hans Dieter
Abstract excerpt
BACKGROUND: Tumour surveillance via induction of TRAIL-mediated apoptosis is a key mechanism, how the immune system prevents malignancy. To determine if gene variants in the TRAIL receptor I (DR4) gene affect the risk of hepatitis C virus (HCV)-induced liver cancer (HCC), we analysed DR4 mutations C626G (rs20575) and A683C (rs20576) in HCV-infected patients with and without HCC. METHODS: Frequencies of DR4 gene...
Read the complete abstract on PubMed